UY39119A - Proteínas de fusión para tratar trastornos metabólicos - Google Patents

Proteínas de fusión para tratar trastornos metabólicos

Info

Publication number
UY39119A
UY39119A UY0001039119A UY39119A UY39119A UY 39119 A UY39119 A UY 39119A UY 0001039119 A UY0001039119 A UY 0001039119A UY 39119 A UY39119 A UY 39119A UY 39119 A UY39119 A UY 39119A
Authority
UY
Uruguay
Prior art keywords
fusion proteins
metabolic disorders
treat metabolic
fgf21
treat
Prior art date
Application number
UY0001039119A
Other languages
English (en)
Inventor
R Boettcher Brian
L Caplan Shari
S Daniels Douglas
Stuart Licht
Craig Weldon Stephen
Norio Hamamatsu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39119A publication Critical patent/UY39119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a la identificación de proteínas de fusión que comprenden variantes polipeptídicas y proteicos del factor de crecimiento de fibroblastos 21 (FGF21) que tienen propiedades farmacéuticas mejoradas. También se describen métodos para el tratamiento de trastornos asociados con el FGF21, incluyendo trastornos metabólicos.
UY0001039119A 2011-09-26 2021-03-08 Proteínas de fusión para tratar trastornos metabólicos UY39119A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
UY39119A true UY39119A (es) 2021-04-30

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
UY34346A UY34346A (es) 2011-09-26 2012-09-25 Proteínas de fusión para tratar trastornos metabólicos
UY0001039119A UY39119A (es) 2011-09-26 2021-03-08 Proteínas de fusión para tratar trastornos metabólicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY34346A UY34346A (es) 2011-09-26 2012-09-25 Proteínas de fusión para tratar trastornos metabólicos

Country Status (41)

Country Link
US (6) US9006400B2 (es)
EP (2) EP3321276B1 (es)
JP (4) JP6186361B2 (es)
KR (1) KR102085605B1 (es)
CN (2) CN107266579B (es)
AP (1) AP2014007543A0 (es)
AR (2) AR088044A1 (es)
AU (1) AU2012316052A1 (es)
BR (1) BR112014007069B1 (es)
CA (1) CA2849464C (es)
CL (2) CL2014000736A1 (es)
CO (1) CO6920257A2 (es)
CR (1) CR20140140A (es)
CU (2) CU24314B1 (es)
CY (2) CY1120928T1 (es)
DK (2) DK2760475T3 (es)
EA (1) EA039633B1 (es)
ES (2) ES2895080T3 (es)
GT (1) GT201400055A (es)
HK (1) HK1251238A1 (es)
HR (2) HRP20211575T1 (es)
HU (2) HUE055584T2 (es)
IL (1) IL231533B (es)
IN (1) IN2014DN02043A (es)
JO (1) JO3476B1 (es)
LT (2) LT3321276T (es)
MA (1) MA35437B1 (es)
MX (1) MX350273B (es)
MY (1) MY166059A (es)
PE (2) PE20181159A1 (es)
PL (2) PL2760475T3 (es)
PT (2) PT2760475T (es)
RS (2) RS57868B1 (es)
SG (2) SG11201400538QA (es)
SI (2) SI3321276T1 (es)
TN (1) TN2014000109A1 (es)
TW (1) TWI593708B (es)
UA (1) UA113856C2 (es)
UY (2) UY34346A (es)
WO (1) WO2013049247A1 (es)
ZA (1) ZA201401700B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3299033A1 (en) 2006-07-25 2018-03-28 Lipoxen Technologies Limited N-terminal polysialylation
KR20160121601A (ko) 2007-03-30 2016-10-19 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
EP4015005A1 (en) 2011-10-03 2022-06-22 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
JP6403685B2 (ja) 2012-12-27 2018-10-17 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
AU2014342630B2 (en) 2013-10-28 2020-11-05 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
ES2808340T3 (es) 2014-01-24 2021-02-26 Ngm Biopharmaceuticals Inc Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos
WO2015138278A1 (en) * 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
PL3412302T3 (pl) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR20180035852A (ko) * 2015-08-03 2018-04-06 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
CN109789186A (zh) * 2016-05-25 2019-05-21 得克萨斯系统大学评议会 用于治疗分泌性疾病的方法和组合物
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
EP3558341A1 (en) 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
CA3062473A1 (en) 2017-05-05 2018-11-08 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN115109166A (zh) * 2017-11-24 2022-09-27 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
EP3727423B1 (en) 2017-12-22 2024-05-22 Novartis AG Treatment of metabolic disorders with fgf21 variants
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
JP2023507364A (ja) 2019-12-20 2023-02-22 ノバルティス アーゲー インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
AU2458001A (en) 1999-12-23 2001-07-03 Zymogenetics Inc. Method for treating inflammation
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CN1890371A (zh) * 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
DK1751184T3 (da) * 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
EA011390B1 (ru) * 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN102264697B (zh) 2008-10-24 2015-09-09 Irm责任有限公司 生物合成产生的吡咯啉-羧基-赖氨酸以及通过吡咯啉-羧基-赖氨酸和吡咯赖氨酸残基化学衍生化的位点特异性蛋白修饰
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
NZ596037A (en) * 2009-05-05 2013-10-25 Amgen Inc Fgf21 mutants and uses thereof
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
SI2760475T1 (sl) 2018-10-30
BR112014007069A2 (pt) 2017-03-28
IL231533A0 (en) 2014-04-30
EP3321276B1 (en) 2021-07-28
MY166059A (en) 2018-05-22
TN2014000109A1 (en) 2015-07-01
CY1120928T1 (el) 2019-12-11
TWI593708B (zh) 2017-08-01
CU20150171A7 (es) 2016-07-29
AP2014007543A0 (en) 2014-03-31
EP2760475B1 (en) 2018-07-04
JP2014534172A (ja) 2014-12-18
JP6186361B2 (ja) 2017-08-23
WO2013049247A1 (en) 2013-04-04
PE20181159A1 (es) 2018-07-19
SG11201400538QA (en) 2014-06-27
PT2760475T (pt) 2018-10-25
EA201490695A1 (ru) 2015-10-30
CL2014000736A1 (es) 2014-10-03
CU24314B1 (es) 2018-02-08
RS62341B1 (sr) 2021-10-29
JP2018023370A (ja) 2018-02-15
IL231533B (en) 2018-06-28
SG10201602339XA (en) 2016-05-30
HUE055584T2 (hu) 2021-12-28
JP2022058546A (ja) 2022-04-12
RS57868B1 (sr) 2018-12-31
LT2760475T (lt) 2018-10-25
US9266935B2 (en) 2016-02-23
US20180369332A1 (en) 2018-12-27
US11129874B2 (en) 2021-09-28
KR102085605B1 (ko) 2020-03-06
HRP20181558T1 (hr) 2018-11-30
PL3321276T3 (pl) 2022-01-17
JP7339372B2 (ja) 2023-09-05
PE20141551A1 (es) 2014-10-26
PL2760475T3 (pl) 2018-11-30
DK3321276T3 (da) 2021-10-25
JP6567613B2 (ja) 2019-08-28
NZ622998A (en) 2016-07-29
TW201326213A (zh) 2013-07-01
CL2016002215A1 (es) 2016-10-28
MX350273B (es) 2017-08-31
EP2760475A1 (en) 2014-08-06
AR123908A2 (es) 2023-01-25
HUE039857T2 (hu) 2019-02-28
IN2014DN02043A (es) 2015-05-15
BR112014007069B1 (pt) 2020-12-15
US11944664B2 (en) 2024-04-02
UY34346A (es) 2013-04-30
CY1124697T1 (el) 2022-07-22
ES2895080T3 (es) 2022-02-17
GT201400055A (es) 2017-09-28
US20150166622A1 (en) 2015-06-18
US20240261372A1 (en) 2024-08-08
JO3476B1 (ar) 2020-07-05
ZA201401700B (en) 2015-01-28
CN103945871B (zh) 2017-04-26
US20130079500A1 (en) 2013-03-28
US20210386824A1 (en) 2021-12-16
US9006400B2 (en) 2015-04-14
MA35437B1 (fr) 2014-09-01
HRP20211575T1 (hr) 2022-02-04
CO6920257A2 (es) 2014-04-10
CR20140140A (es) 2014-07-15
CN107266579A (zh) 2017-10-20
AR088044A1 (es) 2014-05-07
CN107266579B (zh) 2022-07-12
KR20140069250A (ko) 2014-06-09
PT3321276T (pt) 2021-10-27
AU2012316052A1 (en) 2014-04-17
EP3321276A3 (en) 2018-06-20
CU20140034A7 (es) 2014-08-28
US10076554B2 (en) 2018-09-18
CA2849464A1 (en) 2013-04-04
UA113856C2 (xx) 2017-03-27
CN103945871A (zh) 2014-07-23
MX2014003677A (es) 2014-04-30
SI3321276T1 (sl) 2021-11-30
EA039633B1 (ru) 2022-02-18
EP3321276A2 (en) 2018-05-16
DK2760475T3 (en) 2018-10-15
ES2689762T3 (es) 2018-11-15
US20160193297A1 (en) 2016-07-07
JP2020007314A (ja) 2020-01-16
HK1251238A1 (zh) 2019-01-25
CU24206B1 (es) 2016-10-28
CA2849464C (en) 2024-01-30
LT3321276T (lt) 2021-11-10

Similar Documents

Publication Publication Date Title
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
UY33739A (es) Metodos de tratamiento de trastornos asociados con el fgf21
CU20140035A7 (es) Proteínas de función dual para tratar trastornos metabólicos
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20220506